durvalumab,oleclumab
astrazeneca
['synergy', 'durva', 'oleclumab', 'tnbc']
at #esmo22, showed the results of primary endpoint of #synergy (ph2, randomized trial testing #oleclumab + durvalumab + ct in tnbc in 1st line). no improvement in 24-wks cbr in oleclumab arm; interesting exceptional long lasting responses in both arms. 
MD, Medical Oncologist????•Research Fellow at @JulesBordet Institute in Brussels???? Great interest in #BreastCancer and #ImmunoOncology